A review of prescribing patterns among cardiologists at the University of Mississippi Medical Center between 2013 and 2019 found SGLT2 inhibitors prescribed in just 1.4% of patients with T2DM and cardiovascular disease [47]. Here, SLC5A2 is linked to type 2 diabetes mellitus.